About: Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $23.00 (-4.84%)
TNGX NASDAQ Tango Therapeutics Inc
Tango Therapeutics Inc share price
TNGX price activity
Last Price
$23.000
Change (24hr)
-1.17 USD (-4.84%)
Volume
828.52K
Volume (4w avg)
-
Open
$23.85
Day Range
$23.00 - $23.85
Previous Close
$24.17
Last Trade
13 Oct, 4:24 pm GMT+0
Delayed
13 Oct, 4:24 pm GMT+0
TNGX price performance
Delayed
13 Oct, 4:24 pm GMT+0
TNGX Market Signals